How to get the most out of bone densitometry. Results can help assess fracture risk and guide therapy

Bone densitometry has well-established usefulness in assessing fracture risk. Anyone with a condition that might reduce bone mass or accelerate bone loss should undergo testing, as should postmenopausal women and perimenopausal women who are undecided about starting estrogen replacement therapy. When stratifying a patient's risk of fracture, clinicians should consider not only BMD but also age, lifestyle, concurrent illness, and family history. Almost all patients with BMD in the osteoporotic range on densitometry should be considered for pharmacologic therapy, and so should many of those with values in the osteopenic range. Periodic retesting with bone densitometry is appropriate to monitor the progress of age-related bone loss and response to therapy. There are differences among skeletal sites used in BMD measurement, particularly regarding response to therapy. In addition, there are differences in calibration among densitometry machines, so whenever possible, serial studies should be done on the same machine and by the same technologist.